Creative Biostructure Unveils Virus Like Particles to Promote The Research in Drug and Antibody Discovery and Characterization

March 28 00:30 2019

New York, Mar 27th, 2019 – Creative Biostructure, the world’s leading supplier specialized in providing contract services to both academic and biotech/pharmaceutical industries in the field of structural biology, recently unveiling one of its acclaimed products, that is virus-like particles. With these products releasing, Creative Biostructure aims to promote the development of vaccinology as well as other drug discovery.

 

Currently, virus-like particles (VLPs) have evolved into widely accepted technologies, particularly in the field of vaccinology. In fact, some VLP-based vaccines are currently used as commercial medical products, and other VLP-based products are at different stages of clinical research. Several significant advantages have been realized in the development of VLPs as gene therapy tools and new nanomaterials. In recent years, these techniques have developed very rapidly to characterize the structural integrity, stability and composition of newly synthesized VLPs, including encapsidated nucleic acids. In addition, some of the modifications required to construct a VLP-based vector of viral origin with defined properties can be provided.

 

Creative Biostructure provides virus-like particles with high concentrations of specific membrane proteins, which can capture conformational intact membrane proteins directly from the cell surface, allowing these complex proteins to operate as soluble proteins. VLPs are produced by components of a variety of viral families, including the Parvoviridae, the retroviridae, the Flaviviridae, as well as bacteriophage. Moreover, they can be produced in a variety of cell culture systems, including bacteria, mammalian cell lines, insect cell lines, yeast, and plant cells. Our VLPs are produced according to customer-specific membrane proteins or can be obtained from the selected ReadyVLP catalog.

 

With providing concentrated membrane proteins in their native conformation, VLPs have become an alternative to living cells, membrane preparations, and detergent-solubilized proteins. As a promotor being applied throughout drug and antibody discovery and characterization, they are also integrated into a wide variety of existing platforms, such as gene therapy, vaccination, nanotechnology and diagnostics, kinetic analysis of antibody binding by biosensor and radioligand and fluorescent binding assays etc.

 

‘In order to guarantee fast delivery of our products on a global scale, we have established a high quality inventory of all our antigens,’ said Jerry Carter, the marketing director of Creative Biostructure, ‘With optimized production process, our customized VLPs are designed to contain high concentrations of specific membrane proteins. And this whole process includes optimization of membrane protein expression and incorporation.’

 

About Creative Biostructure

Founded in 2005, Creative Biostructure provides scientists with insightful strategies and cost-effective services on structure determination of macromolecules to greatly enhance research performance and promote the development of structural biology. Creative Biostructure is a well-recognized industry leader with more than 10 years of experiences and supports millions of scientists worldwide.

Media Contact
Company Name: Creative Biostructure
Contact Person: Jerry Carter
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States
Website: http://www.creative-biostructure.com